WFDC2 and neoplasm: Emerging biomarkers such as HE4, AFP-L3, and circulating tumor DNA (ctDNA), as well as molecular profiling tools including proteomics and metabolomics, warrant further evaluation for their potential diagnostic and prognostic roles in pediatric oncology [20,21].